

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00241)

APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHAIRMAN OF THE NOMINATION COMMITTEE; AND RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, with effect from December 15, 2025:

- (i) Mr. Shen Difan (“**Mr. Shen**”) has been appointed as the chairman of the Board (the “**Chairman**”) and the chairman of the nomination committee of the Company (the “**Nomination Committee**”); and
- (ii) Mr. Zhu Shunyan (“**Mr. Zhu**”) has tendered his resignation as a non-executive Director, the Chairman and the chairman of the Nomination Committee.

APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHAIRMAN OF THE NOMINATION COMMITTEE

The Board announces that, with effect from December 15, 2025, Mr. Shen, an existing executive Director and the chief executive officer of the Company, has been appointed as the Chairman and the chairman of the Nomination Committee. The Nomination Committee is now composed of one executive Director, namely Mr. Shen as the chairman and two independent non-executive Directors, namely Dr. Shao Rong and Ms. Wu May Yihong.

Code provision C.2.1 of the Corporate Governance Code as set out in Appendix C1 to the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. Accordingly, the appointment of Mr. Shen, an executive Director and the chief executive officer of the Company, as the Chairman deviates from the relevant code provision.

The Board believes that the current leadership structure provides the Company with continuity of experience, strong and consistent leadership, and a unified voice in articulating the Company’s business and strategy. At the same time, the Board upholds an active oversight framework with robust checks and balances to protect the interests of the Company and its shareholders. The Board will continue to assess the effectiveness of the Company’s leadership structure while fulfilling its fiduciary duty to determine the governance structure that best serves the interests of shareholders.

The biography of Mr. Shen is set out below:

Shen Difan, aged 47, was appointed as an executive Director and chief executive officer of the Company on October 13, 2021 and November 28, 2023, respectively. He currently also serves as a director of certain subsidiaries of the Company. From October 2020 to November 28, 2023, he served as the chief operating officer of the Company. He has been a special assistant to the chairman of the board of directors of Alibaba Group Holding Limited (“**Alibaba Holding**”, together with its subsidiaries, “**Alibaba Group**”) from March 2020 to October 2021. Mr. Shen was an executive Director and chief executive officer of the Company from March 2018 to March 2020. Prior to the previous term with the Company, he was the general manager of Alibaba Group’s AliExpress business from March 2012 to March 2018, leading the rapid expansion of AliExpress and growing Alibaba Group’s overseas brand influence. Mr. Shen had held various positions in Alibaba Group since he joined in 2004. Mr. Shen holds a Bachelor Degree in Computing from Yantai University in the PRC.

As at the date of this announcement, Mr. Shen beneficially held 1,764,375 ordinary shares of the Company and, subject to vesting, is interested in 7,997,450 shares underlying the 6,362,450 share options and 1,635,000 restricted share units granted to him in accordance with the Company's share award schemes.

Save as disclosed herein and as at the date of this announcement, Mr. Shen (i) is not interested or deemed to be interested in any shares or underlying shares of the Company pursuant to Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iii) does not hold any directorship in any other Hong Kong or overseas listed public companies in the last three years preceding the date of this announcement, or any other position within the Company or other members of the Group.

Mr. Shen has entered into an appointment letter as an executive Director with the Company for a term of one year commenced from October 13, 2023, which is renewable for a one-year period upon expiry of each term. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the provisions of the bye-laws of the Company and the Listing Rules. There is no separate service contract in relation to Mr. Shen's appointment as the Chairman. Mr. Shen's remuneration package shall remain the same following his appointment as the Chairman.

Save as disclosed herein, Mr. Shen has confirmed that there is no other information required to be disclosed in accordance with Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter relating to his appointment as the Chairman that needs to be brought to the attention of the shareholders of the Company.

The Board would like to congratulate Mr. Shen on his new appointment.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board further announces that Mr. Zhu has tendered his resignation as a non-executive Director, the Chairman and the chairman of the Nomination Committee with effect December 15, 2025 due to the arrangement of his personal affairs.

Mr. Zhu has confirmed that he has no disagreement with the Board and that there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange. The Board would like to take this opportunity to express its sincere gratitude to Mr. Zhu for his valuable contributions during his tenure of directorship with the Company.

For and on behalf of the Board
Alibaba Health Information Technology Limited
Shen Difan
Chief Executive Officer and Chairman

Hong Kong, December 15, 2025

As at the date of this announcement, the Board comprises Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Ms. Huang Jiaojiao and Mr. Xu Haipeng as the non-executive Directors; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.